Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

24 of 28+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, United States· US$2,729,322 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, United States· US$514,864 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, United States· US$518,589 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, United States· US$130,125 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, United States· US$613,866 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 74 running projects, newest first. Listed amounts together: US$30.6m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

  NCT05582031· Translational Research in Oncology· Updated 7 Jun 2023

  “Study never started/ will not proceed.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

  NCT04934722· Merck Sharp & Dohme LLC· Source

• Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT06866548· Shanghai Changzheng Hospital· Source

• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

  NCT02861573· Merck Sharp & Dohme LLC· Source

• Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

  NCT07090148· University of Wisconsin, Madison· Source

• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

  NCT03493945· National Cancer Institute (NCI)· Source

• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

  NCT04580485· Incyte Corporation· Source

• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

  NCT03834519· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Patient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis.

  Cancer Lett, Aug 2026

• Establishment and Characterization of Patient-Derived Xenograft Organoids for Personalized Treatment of Castration-Resistant Prostate Cancer.

  Prostate, May 2026

• Protocol for generating and characterizing Matrigel-free prostate cancer patient-derived organoids.

  STAR Protoc, Apr 2026

• Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

  Eur Urol Oncol, Apr 2026

• Unmasking prostate cancer risk factors leveraging organoid technology.

  Gene, Apr 2026

• Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss.

  Cell Rep Methods, Mar 2026

• [Construction of a membrane-anchored bifunctional growth factor mimetic and its application in organoid culture].

  Sheng Wu Gong Cheng Xue Bao, Mar 2026

• Generation of a Mouse Prostate Organoid-Based Model for Studying Host-Pathogen Interactions.

  J Vis Exp, Feb 2026

• FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.

  Cell Rep, Jan 2026

• Adiponectin receptor agonist, AdipoRon, reduces the growth of prostate cancer cells and patient-derived organoids.

  Life Sci, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.